oral glp 1 agonist for type 2 diabetes Clinical Focus on GLP-1 Agonists in Mellitus Orforglipron, an Oral Small-Molecule GLP-1

2024;48(1 Suppl 1):s181-s206

Diabetes Obes Metab (2016) 18:4919

2017a;40:11724

Liraglutide suppresses TNF- and monocyte chemoattractant protein-1 (MCP-1) expression in monocytes derived from healthy participants

The relationship between GLP-1 therapies and atrial fibrillation is an emerging topic in diabetes care, raising an important question: could medications designed to protect the heart also influence its rhythm

In some patients, it shows a weight-reducing effect of nearly 30 percent, a level expected when conducting obesity metabolic surgery. Park added all these show obese people can reduce weight to a certain extent without surgeries